Health Problems

ALKS 3831

Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review DUBLIN, Nov. 17, 2020 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with […]